Telix Pharmaceuticals
The Quality Control Validation Lead supports the startup and readiness of Quality Control laboratories across the Telix Manufacturing Solution network, providing technical and quality oversight for laboratory commissioning, qualification, validation, and testing processes. This highly mobile, on-site role requires extensive travel to multiple U.S. manufacturing sites to establish compliant QC operations, transfer and validate methods, and maintain inspection readiness. The position partners with various internal and external teams to support regulatory submissions and ensure operational readiness for clinical and commercial manufacturing.
Headquarters
North Melbourne, Victoria, Australia
Company Size
201-500 employees
Founded
2015
Telix Pharmaceuticals is a global, commercial‑stage biopharmaceutical company developing diagnostic and therapeutic “theranostic” products that use targeted radiation to detect and treat cancer. It advances radiopharmaceuticals through clinical development, regulatory approval, manufacturing and commercialisation to bring imaging agents and targeted therapies to patients. Telix works with the nuclear medicine community and international partners to scale access and improve outcomes. Its stated mission is to help patients with cancer live longer with better quality lives.
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Dec 14, 2025
Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX
Nov 13, 2025
Pharma groups rush to calm investor fears over Trump’s tariff hit
Sep 26, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Telix Pharmaceuticals.
The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31, 2025